Key Insights Using the 2 Stage Free Cash Flow to Equity, Vertex fair value estimate is US$32.91 Vertex's US$19.50 ...

The firm said its upgrade reflects increased revenue forecasts for Vertex’s renal programs and higher valuation multiples, lifting its price target to $572. Bernstein sees a high probability that ...

Vertex and Medtronic could see strong momentum this year, while Pfizer is still facing challenges. Regardless of what happens ...

The cost of medication was too high for thousands of CF sufferers around the world. Now a Bangladeshi company is making a generic version that will change lives ...

Robots may not be taking the place of researchers in lab coats running clinical trials anytime soon, but AI is playing an increasingly important role in drug discovery efforts. That’s the message ...

This strengthens Google’s position against rivals such as Microsoft and AWS as enterprises seek faster, more reliable ways to deploy and manage AI agents. Google Cloud has updated its Vertex AI Agent ...

Vertex delivered a split result this morning that left investors parsing mixed signals. The tax technology provider beat on EPS but missed revenue expectations. Shares were down nearly 10% by the ...

(RTTNews) - Vertex, Inc. (VERX) revealed a profit for third quarter that Decreased from last year but beat the Street estimates. The company's bottom line came in at $4.04 million, or $0.02 per share.

Even amid political pressure from RFK Jr. and President Trump, as well as failed clinical data on VX-993, Vertex continues to strengthen its position in the cystic fibrosis market. Sales of its three ...

Vertex Pharmaceuticals remains a buy, anchored by its dominant cystic fibrosis (CF) franchise and optionality in JOURNAVX. VRTX's near-term growth hinges on JOURNAVX's commercial ramp and pivotal ...